Crude and adjusted HRs and 95% CIs for Product D vs Product E in the primary analysis (PA) and 10 sensitivity analyses (SAs). Three outcomes are shown: all inhibitors, high-titer inhibitors, and inhibitors subsequently treated with a bypassing agent and/or ITI (detailed results are presented in supplemental Tables 6-15).